

BMJ Open Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries

Caroline E Boeke ¹, Clement Adesigbin,² Olayinka Adisa,³ Chukwuemeka Agwuocha,³ Muhammad-Mujtaba Akanmu,³ Atiek Anartati,⁴ Khin Sanda Aung,⁵ Amy Azania,¹ Ruth Bello Nabe,⁶ Arief Budiman,⁴ Yuhui Chan,¹ Umesh Chawla,⁷ Fatchanurliyah,⁸ Oriel Fernandes,¹ Gagandeep Singh Grover,⁹ Thandar Su Naing,¹⁰ Dang Ngo,¹¹ Christian B Ramers,¹ Sean Regan,¹ Siddharth Sindhwani,⁷ Gertrudis Tandy,⁸ Khin Tint,¹⁰ Kinh Van Nguyen,¹² Magdalena Witschi,¹ Craig McClure¹

To cite: Boeke CE, Adesigbin C, Adisa O, *et al.* Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. *BMJ Open* 2022;**12**:e062745. doi:10.1136/bmjopen-2022-062745

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-062745>).

Received 09 March 2022
Accepted 08 November 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Caroline E Boeke;
caroline.boeke@mail.harvard.edu

ABSTRACT

Objectives Given limited data on factors associated with hepatitis C virus (HCV) treatment discontinuation and failure in low- and middle-income countries, we aimed to describe patient populations treated for HCV in five countries and identify patient groups that may need additional support.

Design Retrospective cohort analysis using routinely collected data.

Setting Public sector HCV treatment programmes in India (Punjab), Indonesia, Myanmar, Nigeria (Nasarawa) and Vietnam.

Participants 104 957 patients who initiated treatment in 2016–2022 (89% from Punjab).

Primary outcomes Treatment completion and cure.

Results Patient characteristics and factors associated with outcomes varied across countries and facilities. Across all patients, median age was 40 years (IQR: 29–52), 30.6% were female, 7.0% reported a history of injecting drugs, 18.2% were cirrhotic and 4.9% were coinfecting with HIV. 79.8% were prescribed sofosbuvir+daclatasvir. Of patients with adequate follow-up, 90.6% (89,551) completed treatment. 77.5% (69,426) of those who completed treatment also completed sustained virological testing at 12 weeks (SVR12), and of those, 92.6% (64 305) were cured. In multivariable-adjusted models, in most countries, significantly lower treatment completion was observed among patients on 24-week regimens (vs 12-week regimens) and those initiated in later years of the programme. In several countries, males, younger patients <20 years and certain groups of cirrhotic patients were less likely to complete treatment or be cured. In Punjab, treatment completion was also lower in those with a family history of HCV and people who inject drugs (PWID); in other countries, outcomes were comparable for PWID.

Conclusion High proportions of patients completed treatment and were cured across patient groups and countries. SVR12 follow-up could be strengthened. Males, younger people and those with decompensated cirrhosis on longer regimens may require additional support to complete treatment and achieve

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This is a large, multicountry analysis of data from over 100 000 patients on real-world implementation of public sector hepatitis C programmes in low-income and middle-income countries.
- ⇒ Multivariable-adjusted estimates were calculated to identify patient groups at risk for treatment discontinuation and failure.
- ⇒ Routine data from health facilities were used for this analysis; therefore, some data points may be inaccurate.
- ⇒ The majority of the data (89%) came from the programme in Punjab, India, and statistical power was limited for some of the analyses in the other countries.
- ⇒ This analysis was observational in nature, so associations identified cannot be interpreted causally and may be subject to residual confounding.

cure. Adequate programme financing, minimal user fees and implementation of evidence-based policies will be critical to close gaps.

BACKGROUND

Hepatitis C virus (HCV) is curable with generic, well-tolerated direct acting antivirals (DAA) that are now available at low cost in many low- and middle-income countries (LMIC)—as low as US\$60 for World Health Organization (WHO) prequalified products.¹ Initial public sector HCV testing and treatment programmes have demonstrated remarkable success in LMIC, even with limited funding.² However, gaps remain, including initiating people living with HCV (PLHCV)

on treatment and ensuring that PLHCV complete prescribed regimens and are confirmed cured. Better understanding is needed of the patient population on treatment in public sector programmes. Providing additional support to patients who may be at greater risk of treatment discontinuation or failure will be critical for programme success.

While there is some evidence on patient-level characteristics that predict treatment discontinuation and failure in high-income countries, there are very limited data from LMIC. The WHO estimates that only 13% of PLHCV globally have been treated.³ A review of the evidence published in 2020 summarised that across published studies globally, only a median of 29% (range: 12%–77%) of patients diagnosed with chronic HCV initiate treatment.⁴ Of those who initiated treatment, a median of 3% (range: 0%–11%) of patients discontinued treatment and a median of 5% (range: 0%–25%) of patients completed treatment but did not complete sustained virological response testing at 12 weeks (SVR12).⁴ However, gaps are likely to be greater in large public sector programmes in LMIC; indeed, in a separate 2020 analysis of data across 7 LMIC using routinely collected aggregate programme data, while data on treatment completion was not available, the number of patients with an SVR12 test conducted was 45% lower than the number of patients who initiated treatment, indicating substantial gaps in patient follow-up.²

Previous studies have identified predictors of treatment discontinuation and/or loss to follow-up in the HCV care cascade, including younger age,^{4–7} male gender,^{5,6} history of injecting drugs^{4,8} and a history of psychiatric illness.^{4,6} Patient-level predictors of DAA treatment failure (outside of treatment regimen and duration) reported previously include cirrhosis, genotype 1a or 3 infection, resistance-associated variants, elevated viral load (VL), (possibly) HIV coinfection, and previous treatment failure for HCV.^{9–14} However, the bulk of previous evidence on this topic is from high-income countries.

Given the evidence gap in this area, we retrospectively analysed routinely collected public sector monitoring and evaluation (M&E) data from initial programmes in Punjab, India; Indonesia; Myanmar; Nasarawa, Nigeria; and Vietnam, with the aim to describe the characteristics of patients treated for HCV across country programmes, calculate the proportion of patients who completed treatment (defined differently across country contexts as not collecting all medication refills or being lost to follow-up), completed SVR12 testing, and were cured, and identify demographic or clinical factors that may be linked to treatment completion and/or cure. Given that most countries only collected individual-level data for patients treated for HCV (with only aggregate-level data available on screening and diagnosis), this analysis focused on patients who initiated treatment.

METHODS

Country selection and description

We previously published a description of implementation of initial HCV testing and treatment programmes in the public sector in Punjab, India, Indonesia, Myanmar, Nasarawa, Nigeria and Vietnam as well as Cambodia, Indonesia and Rwanda (aggregate cascade of care data only).² Programme strategy and rollout have been supported by the Clinton Health Access Initiative (CHAI), a technical assistance partner that operates hand-in-hand with governments to provide guidance on programme implementation. Leveraging context-specific strategies, all countries have rapidly expanded access to HCV cure by combining market-shaping to reduce prices with simplification of patient pathways. Programmes were provided with CHAI-supported Bristol Myers Squibb donations of daclatasvir (DCV). As part of this support, five countries had individual-level M&E data that could be used for this analysis and obtained relevant institutional review board (IRB) approval. More information on each country is provided in [table 1](#).

In brief, these programmes ranged from a pilot at a small number of facilities (Vietnam) to programmes limited to a particular state (Nasarawa, Nigeria and Punjab, India) to a national programme (Indonesia, Myanmar). Programmes have moved towards operating under a simplified algorithm as outlined in the 2018 WHO guidelines¹⁵ involving a rapid diagnostic test to screen for anti-HCV antibodies, a VL test to assess viraemia, the 12–24 weeks DAA regimen for viraemic patients involving monthly prescription refills and an SVR test 12 weeks after treatment completion. During this period, Vietnam's programme also included, where accessible, genotyping prior to treatment initiation and VL monitoring of those on treatment, in addition to the WHO recommended diagnostic algorithm; the updated guidelines no longer include these additional components.¹⁶

Data collection

Routinely collected M&E data were used for analysis of patients who initiated HCV DAAs for treatment. Deidentified data were collected retrospectively from patient testing and treatment registers, laboratory logbooks, pharmacy records and/or patient charts (dependent on the data systems in each country). In Nasarawa, Nigeria and Vietnam, data were collected manually from paper documents at the facility. In Punjab, India, Indonesia and Myanmar, data were received from government electronic databases. Due to logistical constraints, data time periods and coverage differed by country based on what was available and time period/coverage of IRB approval for analysis; details can be found in [table 1](#). In addition, data points available and definitions of variables varied by country. For instance, designation of cirrhosis status differed based on criteria within the country guidelines at the time and also may have included less objective clinical designation in some cases; the determination of treatment completion also varied. Details can be found in

Table 1 Characteristics of country programmes contributing data

	Punjab, India	Indonesia	Myanmar	Nasarawa, Nigeria	Vietnam
Year of programme initiation	2016*	2017	2017	2015	2017
Time period of data included	February 2016–June 2021	January 2017–February 2022	June 2017–March 2018	July 2017–December 2020	June 2017–December 2018
Data retrieval date	June 2021	March 2022	March 2020	January 2021	January 2019
Scope of data collected	Initial patients treated and longer term scale-up	Initial patients treated and longer-term scale-up	Initial patients treated only	Initial patients treated only	Initial patients treated only
Data source	Custom web-based system	Excel and custom web-based system	Electronic case-based medical record system (OpenMRS)	Paper records at facilities	Paper records at facilities
Geographic coverage of data collected	1 state	17 provinces	3 states and regions	1 state	7 provinces
N and type of health facilities/sites included	59—hospitals, HIV treatment centres, opioid substitution therapy centres and prisons	38—national referral hospitals, provincial hospitals and district hospitals, prison hospitals, military hospitals, police hospitals and one private hospital	8—general hospitals, specialist hospitals	2—outpatient and internal medicine departments from a general hospital and a specialist hospital	8—two national hospitals, five provincial hospitals and one district health centre
N patients included	93 460	7424	2065	139	1869
% of all data covered during time period on public sector DAA initiations	100	100	100	8.1	100
Programme approach to case-finding	General adult population, PLHIV, PWID, prisoners, patients from private sector tested positive	Patients at internal medicine/liver wards, PLHIV at treatment centres, PWIDs, prisoners, haemodialysis patients	Patients at medical wards, PLHIV, PWIDs, men who have sex with men, female sex workers, multi-transfused recipients, HCW, haemodialysis patients, patients from private sector or blood donors tested positive and eligible for public sector care	General adult population (provider-initiated testing and counselling), PLHIV, PWID	PLHIV, PWID, HCW, patients at liver wards; 2019 campaign targeting general population in one province
Patient screening, diagnosis and treatment fee structure	Free of charge	Free of charge if patients have national insurance. Non-insured patients pay for consumables and services	Free of charge (PPP patients pay for VL and treatment at subsidised prices)	Out of pocket	Out of pocket or insurance co-pay (DCV free of charge)
Definition of cirrhosis during time period of data included	APRI >2 and FIB-4 >3.25 in adults. Decompensated cirrhosis defined using clinical criteria (or clinician's judgement) and the Child-Pugh staging system.	APRI>1. Patients at the national hospital were staged using Fibroscan >11.7. Data on decompensated cirrhosis not available.	Initially APRI of >2; changed to >1.5 in the National Simplified Treatment Guidelines for HCV published in 2019. Decompensated cirrhosis defined using clinical criteria (or clinician's judgement) and the Child-Pugh staging system.	APRI >2. Data on decompensated cirrhosis not available.	APRI >2 or a Fibroscan >12.5 kPa; patients at provincial and district level facilities were staged using APRI while patients at the national hospital were staged using Fibroscan. Decompensated cirrhosis defined using clinical criteria (or clinician's judgement) and the Child-Pugh staging system.

Continued

**Table 1** Continued

	Punjab, India	Indonesia	Myanmar	Nasarawa, Nigeria	Vietnam
Definition of treatment completion	Picking up the prescription for the final month of treatment	Picking up the prescription for the final month of treatment	Coming for a visit post-treatment completion	Picking up the prescription for the final month of treatment	Patients who did not return for SVR12 testing were called by health facility staff to confirm whether treatment was completed

*The programme was officially launched in June 2016, but a small number of patients initiated in the months prior.
 .APRI, AST to platelet ratio index; DCV, daclatasvir; HCV, hepatitis C virus; HCW, healthcare worker; PLHIV, people living with HIV; PPP, public private partnership; PWID, people who inject drugs; SVR12, sustained virologic response at 12 weeks; VL, viral load.

table 1. In Myanmar, a small number (N=34) of patients had a treatment status listed as ‘unknown’—these were counted as not completing treatment, to be conservative.

Data analysis

StataSE V.17 was used for data analysis. Patient demographic and clinical characteristics were described by calculating the percentage of patients who were in each category, by country and overall as a summary measure. Only patients with adequate follow-up time were included in analyses of patient treatment completion (at least 12 or 24 weeks to complete regimens as appropriate) and cure (at least 12 or 24 weeks to complete regimens as appropriate, plus an additional 12 weeks to complete SVR12 testing; of note, three patients completed treatment and had an early SVR12 test, these outcomes were included). Analyses of predictors were kept separate by country, as there was substantial variability by country and the dataset from India was substantially larger than from other countries. Given that this was an analysis of real-world public sector data, patients were not excluded based on whether current clinical guidelines were followed; for instance, in Punjab, India there were 216 patients initiated on treatment between ages 12–17 that were included in this analysis.

The primary outcomes of the analysis were the proportion of patients who completed treatment (definitions of treatment completion for each country can be found in [table 1](#)) and the proportion who were cured among those who completed SVR12. Analyses were conducted separately by country. Patients who died during follow-up were excluded from these analyses, as information on cause and timing of death was not consistently available. We cross-tabulated patient demographic and clinical characteristics by these outcomes to assess the percentage of patients within each category that completed treatment/achieved cure. To identify variables that were statistically significant predictors of outcomes, multivariable-adjusted generalised linear models accounting for clustering by health facility were used (using the `glm` command with the `cluster` option in Stata). Variables that were individually associated with the primary outcome in one or more countries were considered for inclusion into the multivariable-adjusted model; in the model building process, variables that were not significant in any

country-specific models were removed from the final multivariable-adjusted model. After building models separately for each outcome, the same final list of variables was used for multivariable-adjusted models in each country. The final model with treatment completion as the outcome adjusted for sex, age category, family history of HCV, history of injecting drugs, cirrhosis status, treatment regimen, treatment duration and year of treatment initiation. The final model with cure/treatment failure as the outcome adjusted for sex, age category, family history of HCV, cirrhosis status and treatment regimen. We dropped out variables that were too sparse to be included in the model; that meant that in some countries with smaller datasets (Myanmar and Nasarawa, Nigeria), some variables were omitted from multivariable-adjusted models. In country datasets without a particular variable, this variable was not adjusted for in the analysis. A missing indicator category was included for each variable in the model to account for missing data and minimise loss of statistical power due to missingness. Results were similar when those when missing data were removed from analyses. Statistical significance was defined as $p < 0.05$.

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

RESULTS

Demographic characteristics of patients initiated on treatment

Data from 104 957 patients who initiated HCV treatment in 2016–2022 were included in this analysis. The majority of patients were in the programme from Punjab, India (93,460); in addition, 7424 patients were from Indonesia, 2065 from Myanmar, 139 from Nasarawa, Nigeria and 1869 from Vietnam. Patient demographic and clinical characteristics as well as treatment outcomes are shown by country in [table 2](#).

In terms of gender: 30.6% of patients were female. In Punjab, India, Indonesia and Vietnam, the majority of those being treated were male (69.4% in Punjab, India, 71.2% in Indonesia, 82.3% in Vietnam). This was reflective of a larger proportion of males both getting tested for HCV and testing positive for chronic HCV and a

Table 2 Demographic and clinical characteristics of patients who initiated hepatitis C treatment, %

	All	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
N	104957	93460	7424	2065	139	1869
Sex						
Female	30.6%	30.6%	28.5%	47.8%	54.7%	17.7%
Male	69.4%	69.4%	71.2%	52.3%	45.3%	82.3%
Transgender	0.02%	0.02%	0.0%	0.0%	0.0%	0.0%
Missing	0.02%	0.0%	0.3%	0.0%	0.0%	0.0%
Age						
12–19	1.3%	1.4%	0.4%	0.1%	0.0%	0.2%
20–29	24.0%	26.4%	4.7%	3.9%	5.8%	3.9%
30–39	23.0%	22.9%	24.8%	12.8%	13.0%	33.2%
40–49	20.9%	19.5%	32.5%	28.4%	21.6%	36.3%
50–59	15.7%	15.4%	16.0%	31.0%	36.7%	14.2%
60–69	10.8%	10.7%	11.8%	17.0%	14.4%	8.4%
70+	4.0%	3.7%	7.7%	6.7%	8.6%	4.0%
Missing	0.3%	0.2%	2.2%	0.1%	0.0%	0.0%
Family history of HCV						
Yes	0.3%	0.1%	0.0%	9.5%	0.7%	0.0%
None reported	90.9%	99.9%	0.0%	90.5%	99.3%	0.0%
Not available	8.9%	0.0%	100.0%*	0.0%	0.0%	100.0%*
History of injecting drugs						
Yes, reported by patient	7.0%	5.2%	21.1%	11.2%	0.0%	34.5%
None reported	93.0%	94.8%	78.9%	88.8%	100.0%	65.5%
Known HIV coinfection						
Yes	4.9%	2.2%	22.6%	40.2%	2.2%	33.9%
None reported	95.1%	97.8%	77.4%	59.8%	97.8%	66.1%
Known HBV coinfection						
Yes	0.2%	0.0%	0.0%	3.4%	7.2%	5.5%
None reported	92.8%	100.0%	0.0%	96.6%	92.8%	94.5%
Not available	7.1%	0.0%	100.0%*	0.0%	0.0%	0.0%
HCV genotype						
1	0.7%	0.0%	0.0%	0.0%	1.4%	40.0%
2	0.02%	0.0%	0.0%	0.0%	0.0%	1.0%
3	0.1%	0.0%	0.0%	0.0%	0.0%	3.0%
6	0.7%	0.0%	0.0%	0.0%	0.0%	37.0%
Not available/missing	98.6%	100.0%*	100.0%*	100.0%*	98.6%	19.0%
Cirrhosis						
Compensated	8.3%	8.1%	0.0%	17.1%	0.0%	38.8%
Decompensated	1.0%	0.9%	0.0%	8.7%	0.0%	2.4%
Cirrhotic (no additional information)	8.9%	7.0%	38.1%	0.0%	5.0%	0.0%
Non-cirrhotic	81.8%	84.0%	61.8%	74.3%	95.0%	58.8%
Missing	0.01%	0.0%	0.1%	0.0%	0.0%	0.0%
Treatment regimen						
SOF/DCV	79.0%	78.9%	78.3%	100.0%	100.0%	62.7%
SOF/DCV+RBV	0.8%	0.1%	1.3%	0.0%	0.0%	37.3%
SOF/VEL	7.6%	8.5%	0.0%	0.0%	0.0%	0.0%
SOF/VEL+RBV	11.1%	12.5%	0.0%	0.0%	0.0%	0.0%
Other	1.5%	0.0%	20.4%	0.0%	0.0%	0.0%
Treatment duration						
12 weeks	88.0%	90.4%	62.4%	67.3%	95.0%	90.5%

Continued

Table 2 Continued

	All	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
24 weeks	11.8%	9.3%	37.6%	32.7%	5.0%	9.2%
Other	0.2%	0.2%	0.0%	0.0%	0.0%	0.3%
Year of treatment initiation						
2016	18.6%	20.9%	0.0%	0.0%	0.7%	0.0%
2017	22.5%	21.2%	18.0%	80.9%	10.8%	40.4%
2018	19.3%	17.9%	25.9%	19.1%	43.2%	59.6%
2019	22.0%	22.3%	29.2%	0.0%	45.3%	0.1%
2020	11.4%	12.4%	4.3%	0.0%	0.0%	0.0%
2021	6.2%	5.2%	21.3%	0.0%	0.0%	0.0%
2022	0.1%	0.0%	1.4%	0.0%	0.0%	0.0%
Outcome (N=100 101)†						
Confirmed cured via SVR12	64.2%	66.5%	34.8%	79.8%	25.9%	61.2%
Failed treatment	5.1%	5.5%	1.2%	8.6%	2.2%	0.4%
Did not complete treatment	9.3%	8.6%	20.4%	1.5%	13.7%	6.3%
Completed treatment but did not return for SVR12	20.1%	18.2%	42.0%	8.6%	58.3%	32.0%
Died	1.2%	1.2%	1.6%	1.6%	0.0%	0.2%

*This information was not collected/not available in the database.

†A total of 4856 patients did not have adequate follow-up time in the dataset to complete treatment based on date of treatment initiation and date of data collection, and therefore, were excluded from this and all subsequent analyses.

DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks; VEL, velpatasvir.

higher proportion of people who inject drugs (PWIDs) being male in those countries (>92%). In Myanmar and Nasarawa, Nigeria, the proportion of males and females treated were closer to equal. In terms of age: the median age was 40 years (IQR: 29–52), with the youngest population in Punjab's programme (50.7% were age 39 years or younger) and older populations in Myanmar (54.7% were age 50+ years) and Nasarawa, Nigeria (59.7% were age 50+ years).

In terms of other demographic characteristics: 0.3% reported a family history of HCV. 7.0% had a reported history of injecting drugs, most common among programme participants in Vietnam (34.5%) and Indonesia (21.1%), where this population was a focus of the programme, and in Myanmar (11.2%) where PWID and cirrhotic patients were prioritised for the limited, free-of-charge public treatment courses. 4.9% of patients were reported or confirmed to be coinfecting with HIV, ranging from 2.2% in Punjab, India and Nasarawa, Nigeria to much higher in Myanmar, Vietnam and Indonesia (40.2%–33.9% and 22.6%, respectively), whose programmes had a focus on coinfection or prioritisation of free treatment for coinfecting patients. 0.2% had known coinfection with hepatitis B virus and 0.02% with tuberculosis (data not shown).

Clinical characteristics

The proportion of patients with cirrhosis varied across countries: 41.2% in Vietnam (38.8% compensated and 2.4% decompensated), 38.1% in Indonesia (no information available in database on type of cirrhosis), 25.8% in Myanmar (17.1% compensated and 8.7%

decompensated), 16.0% in Punjab, India (8.1% compensated, 0.9% decompensated, 7.0% with no further information on type of cirrhosis) and 5.0% in Nasarawa, Nigeria (where cirrhosis data were missing for many patients and largely presumed based on duration of prescribed treatment). In Vietnam, the most common genotypes were 1 (40.0%) and 6 (37.0%); a small proportion were genotype 3 (3.0%) and 19.0% did not have genotype data available. In terms of treatment regimen: In Myanmar, Nasarawa, Nigeria and Vietnam, all patients were prescribed sofosbuvir/DCV (SOF/DCV)-based regimens. In Indonesia, 79.6% were prescribed SOF/DCV-based regimens and the remaining patients were on other regimens including SOF+simeprevir-based regimens and elbasvir/grazoprevir. In Punjab, India, 79.0% were prescribed SOF/DCV based regimens and 21.0% were prescribed SOF and velpatasvir (SOF/VEL)-based regimens. In India and Vietnam, ribavirin (RBV) was added to treatment for some cirrhotic patients due to lower cost, whereas in Nasarawa, Nigeria and Myanmar, cirrhotic patients were typically prescribed 24 weeks of SOF/DCV. In terms of treatment duration: >90% of patients in Punjab, India, Nasarawa, Nigeria and Vietnam were prescribed 12 weeks of treatment; in Indonesia 37.6% of patients were prescribed 24 weeks of treatment and in Myanmar, 32.7% of patients were prescribed 24 weeks of treatment.

Treatment outcomes

Of 100 101 patients who initiated treatment and had adequate follow-up time in the dataset to assess treatment completion, 1244 deaths were reported (note: deaths were not routinely assessed in all contexts and were

not necessarily related to HCV). Among the remaining patients, 90.6% (89 551) completed treatment. 77.5% of patients who completed treatment also completed SVR12 testing (69 432); completion of SVR12 testing was comparatively lower in Nasarawa, Nigeria (32.5% of patients who completed treatment), Indonesia (46.1%) and Vietnam (65.8%). Among patients with SVR12 results, cure rates were >90% across all countries; overall, 92.6% (64 305) were cured.

Predictors of treatment completion

Table 3 reports the percentage of patients who completed treatment disaggregated by demographic and clinical characteristics; more detail on the full multivariable-adjusted regression models by country can be found in online supplemental table 1. Treatment completion was high among most groups. In multivariable-adjusted analyses, in all countries with sufficient sample size, significantly lower treatment completion was observed among patients on 24-week regimens (vs 12-week regimens) (Punjab: 86.5% vs 91.8%, Indonesia: 68.9% vs 85.5%; Myanmar 96.9% vs 99.3%, Vietnam 91.8% vs 93.9%, all $p<0.05$). Significantly lower treatment completion was also observed among those initiated in later years of the programme. In several countries, there was significantly lower treatment completion among younger patients <20 years compared with some or all older age categories (Punjab, India, Myanmar, Vietnam), and certain groups of cirrhotic patients (decompensated patients in Punjab, India and Vietnam, compensated patients in Myanmar and Vietnam) compared with non-cirrhotic patients. In Punjab, India, treatment completion was also lower in males (89.2% vs 96.0%, $p<0.001$), those with family history of HCV (84.1% vs 91.3% in the general population; $p=0.001$), and PWID (76.8% vs 92.0% in the general population, $p=0.03$). In other countries, PWID had comparable outcomes to the general population; in Indonesia, PWID were more likely to complete treatment (88.4% vs 76.8%, $p<0.001$).

In all countries, there were significant differences in treatment completion across health facilities. In Punjab, India and Indonesia, treatment completion varied from <50% to 100% depending on the facility (note: a much larger number of facilities contributed data compared with other countries); in Myanmar, it varied from 96% to 99%, in Nasarawa, Nigeria, it varied from 72% to 95%, and from Vietnam it varied from 85% to 100%.

Predictors of cure

Table 4 reports the percentage of patients who were cured, among those with SVR12 data available, disaggregated by patient characteristics. The full multivariable-adjusted regression model results can be found in online supplemental table 2. In Punjab, India and Myanmar, males who completed SVR12 testing were significantly less likely to be cured compared with females; the opposite was true in Vietnam. In Punjab, India, Indonesia and Myanmar, individuals in the youngest age categories were less likely

to be cured. Cirrhosis category was a significant predictor in Punjab, India, with 91.5% of cirrhotic patients cured compared with 92.4% of non-cirrhotic patients ($p=0.05$) and in Myanmar, with 86.4% of decompensated cirrhotic patients cured compared with 90.7% of non-cirrhotic patients ($p=0.002$). In Punjab, India, patients on SOF/VEL+RBV more likely to be cured compared with SOF/DCV, although the difference between groups was relatively small (94.4% vs 92.1%, $p<0.001$).

In Punjab, India, Indonesia and Vietnam, there were significant differences in cure rates across health facilities. In Punjab, India, cure rates ranged across facilities from <60% (in two facilities with <10 patients treated) to 100%, in Indonesia cure rates ranged from 73% to 100%, and in Vietnam they varied from 92% to 100%. In countries with data on facility level available, strong outcomes were seen across all tiers of health facilities, even smaller health centres without specialists providing care.

DISCUSSION

Summary of key findings

In this analysis of data from over 100 000 patients initiated on DAAs across five different programmes in LMIC, the proportion of patients who completed treatment and were cured was quite high overall and across most patient groups examined. Approximately 90% completed treatment, 77% of those who completed treatment completed SVR12 testing, and 93% of those who completed SVR12 testing were cured. SVR12 testing coverage was limited in Indonesia, Nasarawa, Nigeria and Vietnam. In several countries, males, younger patients and cirrhotic patients were significantly less likely to complete treatment and be cured. Those on 24-week regimens were also less likely to complete treatment across most countries. In Punjab, India, treatment completion was also lower in those with a family history of HCV and in PWID; in other countries, outcomes were comparable or more favourable for PWID and PLHIV. Treatment completion was significantly lower in more recent years of the programme. Within each country, there were significant differences in patient outcomes across health facilities, indicating differences in service delivery and/or patient characteristics at different facilities that could influence outcomes. Additional support may be needed in certain facilities and certain patient groups to ensure treatment completion and confirm cure. The findings from this analysis are encouraging in that in the early phases of these public sector programmes, outcomes demonstrated high treatment completion and a high proportion of patients cured, supporting the feasibility and real-world effectiveness of public sector HCV elimination programmes.

LIMITATIONS

This analysis has a number of limitations. Data were retrospective, routinely collected programme M&E data, so there may be issues with data accuracy and completeness

**Table 3** Treatment completion classified by patient characteristics across countries*

	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
	% completed treatment	% completed treatment	% completed treatment	% completed treatment	% completed treatment
N	79 894/87 522	5785/7297	2003/2033	120/139	1749/1866
Total %	91.3	79.3	98.5	86.3	93.7
Sex					
Female	96.0	78.5	98.7	85.5	94.6
Male	89.2	79.9	98.4	87.3	93.6
Transgender	88.2	–	–	–	–
Unknown	–	0.0	–	–	–
Age					
12–19	83.5	85.7	100.0†	–	100.0†
20–29	86.4	76.2	97.5	100.0†	91.7
30–39	91.7	84.2	98.9	83.3	93.9
40–49	94.8	80.8	98.6	83.3	93.9
50–59	94.5	76.4	99.1	90.2	94.3
60–69	93.1	74.6	97.1	80.0	92.4
70+	90.0	72.4	99.3	83.3	93.2
Missing	91.1	76.9	100.0†	–	–
Family history of HCV					
Yes	84.1	–	99.5	100.0†	–
None reported	91.3	–	98.4	86.2	–
History of injecting drugs					
Yes	76.8	88.4	99.6	–	93.8
None reported	92.0	76.8	98.4	86.3	93.7
Known HIV coinfection					
Yes	75.3	84.7	98.8	100.0†	94.8
No	91.6	77.7	98.4	86.0	93.2
Known HBV coinfection					
Yes	33.3†	–	100.0	100.0	93.1
No	91.3	–	98.5	85.3	93.8
Cirrhosis					
Compensated	89.8%	–	98.3%	–	92.1%
Decompensated	79.5%	–	99.4%	–	93.2%
Cirrhotic (no additional information)	88.4%	69.6%	–	100.0%†	–
Non-cirrhotic	91.7%	85.2%	98.5%	85.6%	94.8%
Missing	–	50%†	–	–	–
Treatment regimen					
SOF/DCV	91.6%	78.9%	98.5%	86.3%	94.1%
SOF/DCV+RBV	64.2%	90.4%	–	–	93.1%
SOF/VEL	89.8%	–	–	–	–
SOF/VEL+RBV	90.3%	–	–	–	–
Other	85.2%	80.0%	–	–	–
Treatment duration					
12 weeks	91.8	85.5	99.3	85.6	93.9%

Continued

Table 3 Continued

	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
	% completed treatment	% completed treatment	% completed treatment	% completed treatment	% completed treatment
24 weeks	86.5	68.9	96.9	100.0†	91.8%
Other	97.2	–	–	–	100.0%†
Year of treatment initiation					
2016	97.1	–	–	0.0†	–
2017	94.0	82.8	98.7	100.0	95.8
2018	92.3	86.0	97.7	91.7	92.4
2019	86.9	84.6	–	79.4	100.0†
2020	83.6	76.9	–	–	–
2021	80.1	66.2	–	–	–
2022	–	0.0	–	–	–

*Patients who died were excluded from this analysis, as the data did not consistently indicate the timing of death (pretreatment or post-treatment completion).
 †Sample size was <10 people in this category.
 DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.

affecting analyses. For instance, 7.0% of patients in the dataset reported history of injecting drugs, lower than might be expected; this could be due to under-reporting by patients and/or inconsistent solicitation/recording of this information by healthcare workers (HCW). In Myanmar, the proportion of patients prescribed 24 weeks of treatment was higher than the proportion classified as cirrhotic, which may relate to clinical discretion/differences in reporting over time. Private sector data were not included. Programmes were implemented differently across country contexts and some country data were limited to the very initial stages of the programme, so it was difficult to make direct comparisons between countries; the older programme data may be less relevant. The majority of the data (89%) came from the programme in Punjab, India, and statistical power was limited for some of the analyses in the other countries. This analysis was observational in nature, so associations identified cannot be interpreted causally and may be subject to confounding. Given the large sample sizes and high level of statistical power, it is possible that some findings were statistically significant due to chance; we focused on risk factors identified as significant across multiple countries or outcomes and those with larger relative differences in outcomes, indicating greater public health relevance. Finally, the dataset was limited to patients who initiated treatment, so it was not possible to assess risk factors for linkage to care which in many contexts may have more patient loss to follow-up than what is observed after treatment initiation. Future studies should focus on risk factors for patient lost to follow-up between diagnosis and treatment initiation.

Predictors of treatment completion and cure

In this analysis, certain populations appeared to be at higher risk of treatment discontinuation. Our finding in Punjab, India that males were less likely to complete treatment has previously been reported in other country contexts showing that males were more likely to be lost to follow-up from HCV services^{5 6} and has also been reported in antiretroviral therapy programmes for PLHIV in LMIC.¹⁷ While a definitive explanation for this finding cannot be provided here, this could be due to males presenting later to care, or reduced integration into the healthcare system in males participating in the programme. Males were also significantly less likely to achieve cure in Punjab, India and Myanmar, which may relate to treatment adherence issues. In certain contexts, this group may benefit from additional follow-up and support to complete their treatment. Similarly, in several countries, adolescents 12–19 years were less likely to complete treatment and, among those with SVR12 results, were less likely to be cured. Younger age has been reported previously as a risk factor for lost to follow-up in HCV programmes^{4–7} and HIV treatment programmes as well,¹⁸ possibly due to stigma, competing priorities or generally feeling healthy. Younger patients may need additional support to ensure adherence and treatment completion. In addition, in several countries, those with cirrhosis and on 24-week treatment regimens (which represented many overlapping patients) were significantly less likely to complete treatment; those with cirrhosis were also less likely to achieve cure in some countries. This could be due to a number of factors including more complications, hospitalisation or death in these patients or pill fatigue on longer regimens. This group

**Table 4** Proportion of patients cured classified by patient characteristics across countries*

	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
	% cured	% cured	% cured	% cured	% cured
N	58 902/63 746	2576/2667	1648/1826	36/39	1143/1151
Total %	92.4	96.6	90.3	92.3	99.3
Sex					
Female	95.0%	96.5%	92.2%	92.9%	98.5%
Male	91.0%	96.6%	88.4%	90.9%	99.5%
Transgender	100.0%	–	–	–	–
Age					
12–19	84.5%†	100.0%	50.0%†	–	100.0%†
20–29	87.5%	94.6%	93.9%	100.0%†	100.0%
30–39	93.4%	97.7%	93.0%	90.0%	99.0%
40–49	94.4%	95.2%	89.0%	100.0%†	99.5%
50–59	94.4%	95.9%	89.5%	100.0%	100.0%
60–69	93.7%	97.6%	91.2%	66.7%†	100.0%
70+	94.3%	98.1%	90.2%	100.0%†	96.0%
Missing	93.6%	95.5%	–	–	–
Family history of HCV					
Yes	97.9%	–	91.4%	100.0%†	–
None Reported	92.4%	–	90.1%	92.1%	–
History of injecting drugs					
Yes	84.6%	96.0%	86.1%	92.3%	99.6%
None reported	92.6%	96.8%	90.8%	–	99.1%
Known HIV coinfection					
Yes	83.2%	97.0%	89.7%	100.0%†	99.6%
No	92.5%	96.4%	90.6%	92.1%	99.1%
Known HBV coinfection					
Yes	–	–	92.1%	66.7%†	98.2%
No	92.4%	–	90.2%	94.4%	99.4%
Cirrhosis					
Compensated	93.0%	–	90.0%	–	99.2%
Decompensated	93.7%	–	86.4%	–	100.0%
Cirrhotic (no additional information)	91.5%	97.0%	–	100.0%†	–
Non-cirrhotic	92.4%	96.4%	90.7%	91.7%	99.3%
Missing	–	100.0%†	–	–	–
Treatment regimen					
SOF/DCV	92.1%	96.5%	90.3%	92.3%	99.5%
SOF/DCV+RBV	81.0%	97.7%	–	–	99.0%
SOF/VEL	91.7%	–	–	–	–
SOF/VEL+RBV	94.4%	–	–	–	–
Other	86.4%	96.7%	–	–	–
Treatment duration					
12 weeks	92.2%	96.4%	90.1%	91.7%	99.3%
24 weeks	93.9%	97.0%	90.5%	100.0%†	100.0%
Other	94.2%	–	–	–	100.0%†

Continued

Table 4 Continued

	India (Punjab State only)	Indonesia	Myanmar	Nigeria (Nasarawa State only)	Vietnam
	% cured	% cured	% cured	% cured	% cured
Year of treatment initiation					
2016	94.2%	–	–	–	–
2017	91.4%	97.8%	90.1%	100.0%†	99.1%
2018	93.4%	95.6%	91.2%	87.5%	99.5%
2019	90.8%	96.7%	–	100.0%†	100.0%†
2020	90.8%	96.7%	–	–	–
2021	76.9%	96.1%	–	–	–

*Among those who completed SVR12 testing.
 †Sample size was <10 people in this category.
 DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.

may need additional support to ensure that they are able to complete treatment.

In general, strong outcomes were seen in both PLHIV and PWID, two vulnerable patient groups. In Indonesia, Myanmar and Vietnam, a high proportion of both PLHIV and PWID completed treatment and were confirmed cured. Vietnam's initial HCV programme targeted these groups for support, and Myanmar and Indonesia's programmes prioritised PWID, PLHIV and cirrhotic patients for the limited courses of free treatment available through the public sector. In these country programmes, a high proportion of patients treated were PLHIV and/or PWID, and HCV care was integrated with other health services. In Punjab, India, where these groups recently have become more of a focus as the programme has expanded, HCV treatment completion was significantly lower among PWID. Of note, the vast majority of PWID in Punjab, India's treatment programme were male and in younger age groups. In some programme contexts, PWID may need additional support to complete treatment.

A lower proportion of patients completed treatment in more recent years of programmes. With greater volumes of patients treated in more facilities over time, individuals may be receiving less support from health workers for adherence and education. This may be a training issue as services are decentralised to lower cadres of health workers; as programmes grow, additional support around patient education and counselling may be needed to encourage all patients to complete treatment.

SVR12 testing coverage and cure

There was room for improvement in the coverage of SVR12 testing (approximately 70% of all patients). Coverage was lowest in Nasarawa, Nigeria, Indonesia and Vietnam. Nigeria and Vietnam are countries with out-of-pocket payment models, although other factors may have contributed. However, overall among patients with SVR12 results, 92% of patients were cured. DAAs are effective in curing most people of HCV, regardless of whether they receive an SVR12 test to confirm this. For

initial programmes operating with limited budgets, it is more cost-effective to focus spending on HCV diagnosis and treatment efforts rather than on SVR12 confirmation. Thus, SVR12 should not necessarily be the primary focus for resource-limited settings. However, mechanisms to confirm treatment completion should be in place.

Treatment outcomes across health facilities

Treatment completion and cure rates varied substantially across health facilities. Strong outcomes were seen across different types of facilities, indicating that programme decentralisation is possible to lower-level health facilities with strong results. However, the variability in outcomes across facilities and over time indicate that there were other factors at the facility and/or patient level that influenced outcomes. On the facility side, this could include differences in staff training and mentorship leading to varying effectiveness of patient education and counselling, impacting outcomes. Staff attitudes towards patients, high staff turnover and/or heightened stigma could have played a role in outcomes at some facilities. Patients seeking care at certain facilities may have had lower incomes on average, and therefore more financial barriers to travelling to the facility, paying for services (depending on the payment model in each country), and ultimately completing treatment. While this analysis looked at patient factors associated with treatment completion, it was limited to characteristics included in patient medical records. Many personal reasons may contribute to treatment discontinuation. Self-perceived reasons for lost to follow-up reported in other studies include limited knowledge and education about HCV,^{5 19} challenges in accessing HCV services,^{5 19} and personal belief that follow-up was not needed.¹⁹ These significant differences in outcomes across health facilities underscore the importance of public sector programmes routinely reviewing programme data by facility to identify health facilities that may need additional support, through refresher trainings and/or other strategies.

Strategies to improve treatment outcomes

A number of evidence-based strategies may be implemented to improve treatment completion and reduce lost to follow-up from HCV programmes. Updated 2022 WHO guidelines recommend simplified service delivery through decentralisation, integration and task sharing, strategies to improve programme outcomes, as well as offering reflex VL testing and point-of-care as an alternative to centralised VL testing.²⁰ In many programmes, excessive visits are required for testing and treatment. Simplifying algorithms to minimise the number of times patients must come to health facilities for care will be an important strategy. This may be done through same day screening and confirmatory VL; support via telemedicine^{21–23}; and multimonth prescription dispensations, a strategy that has been used effectively in Cambodia to streamline number of visits for HCV patients,^{24 25} demonstrated strong SVR12 outcomes across five countries in the MINMON trial,²⁶ and has also been used to streamline ART services for PLHIV. In addition, decentralising care to lower tier health facilities and additional cadres of HCW will improve access and has been shown to have equivalent SVR12 rates compared with care by specialists.²⁷ Clear and comprehensive training materials and a regular training schedule will be necessary to successfully decentralise care to lower tier facilities in the longer term. Integration of services may also improve patient outcomes; in this analysis, programmes that prioritised PLHIV and PWID demonstrated strong outcomes in these groups. A recent meta-analysis reported that integrating HCV care with primary care and harm reduction services/ decentralisation of care may improve linkage to care and treatment access and thus could be an important way to improve follow-up.²⁸ In addition, while many programmes have already built strong data systems, it will be important for systems to track all patients through the testing and treatment process, identifying in real time those who do not come for appointments and prescription refills for follow-up by health facility staff. Some programmes, such as in Punjab, India are already doing this. Automated SMS appointment/treatment refill pickup reminders/results delivery have been effective in other disease programmes such as HIV.²⁹ Programmes in Punjab, India are currently employing this strategy to improve treatment adherence and completion. Myanmar's programme has used automated reporting tools through OpenMRS to create easy-to-access lists of patients for follow-up or SVR12 scheduling that are facilitating efficient HCW phone follow-up. Supportive interventions such as adherence clubs and community-based support have been successful to improve retention in care for PLHIV on ART³⁰ and have been used successfully in HCV programmes in Myanmar³¹ and Vietnam.^{32 33} Finally, ensuring adequate programme financing, including minimal out-of-pocket costs/user fees for testing and treatment and financing to implement these evidence-based policies will be critical to close gaps in service utilisation.

CONCLUSION

Across five LMIC, early public sector programme data demonstrated high treatment completion and cure rates across demographic and clinical groups. These findings are positive and suggest that investments in HCV programmes have strong potential to cure many PLHCV. Males, younger individuals, those with cirrhosis/on longer treatment regimens, and PWID may need additional support in certain contexts to complete their treatment. Decentralised, integrated, and simple HCV diagnosis and treatment programmes, with adequate funding, community engagement, and strong routine data systems to enable real-time programme monitoring and strengthening, will be essential to scale programmes and achieve HCV elimination.

Author affiliations

- ¹Clinton Health Access Initiative, Boston, Massachusetts, USA
- ²National AIDS/STIs Control Programme, Federal Ministry of Health, Abuja, FCT, Nigeria
- ³Clinton Health Access Initiative, Abuja, Nigeria
- ⁴Clinton Health Access Initiative, Jakarta, Indonesia
- ⁵National Hepatitis Control Program, Department of Public Health, Ministry of Health, Naypyidaw, Myanmar
- ⁶Nasarawa State AIDS Control Agency, Nasarawa, Nigeria
- ⁷Clinton Health Access Initiative, Delhi, India
- ⁸Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia
- ⁹State Viral Hepatitis Management Unit, Department of Health and Family Welfare, Government of Punjab, Chandigarh, Punjab, India
- ¹⁰Clinton Health Access Initiative, Yangon, Myanmar
- ¹¹Clinton Health Access Initiative, Hanoi, Viet Nam
- ¹²National Hospital of Tropical Diseases, Hanoi, Viet Nam

Acknowledgements We would like to acknowledge the governments of India, Indonesia, Myanmar, Nigeria and Vietnam; government staff including Dr. Ibrahim Adamu, Dr. Akudo Ikpeazu, Dr. Siti Nadia Tarmizi, Dr. Regina Tiolina Sidjabat, and Dr. Victoria Indrawati; health facility staff; CHAI program staff including: Dr. Robert Kosasih, Dr. Fran Daut Ranto, Dr. Cao Thuy, Jibrin Kama, Folu Lufadeiju, Htet Aung Naing, Christalyn Nant, Thu Nguyen, Trang Nong, Dr. Khin Yi Oo, and Dr. Owens Wiwa; and other key partners for their support of these programmes.

Contributors CB, OF, CBR, SR and CM conceived the idea for the analysis. CB conducted the statistical analysis. CB and CM wrote the original draft. CB, CIA, OA, ChA, M-MA, KSA, AmA, AtA, RBN, AB, YC, UC, OF, F, GSG, TSN, DN, CBR, SR, SS, GT, KT, KVN, MW and CM contributed to subsequent drafts and reviewed and approved the final draft. CB is the guarantor.

Funding This work was supported by the UK Foreign, Commonwealth, and Development Office (FCDO) SHAPE and 3DSHAPE grants.

Disclaimer The funders were not involved in the analysis.

Competing interests Dr. Christian Ramers declares the following competing interests: Consulting: Gilead Sciences, AbbVie, Viiv healthcare, Janssen Speaking/Teaching: Gilead Sciences, Abbvie, Viiv healthcare Grants/research funding to his institution: Gilead Sciences, AbbVie The other authors declare no competing interests.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was obtained from the Centre for Media Studies in New Delhi, India (IRB00006230), Atma Jaya University IRB in Indonesia (0001H/III/LPPPE.PM.10.05/01/2022), University of Public Health IRB, Ministry of Health, the Republic of the Union of Myanmar (2020/Research/3), the National Health Research Ethics Committee of Nigeria (NHREC/01/01/2007), the National Hospital of Tropical Diseases IRB in Vietnam (107/QD-NDTW), the Alfred Ethics Committee in Australia (205/20), and Chesapeake IRB in the USA (Pro00025218 and Pro00024736). As this was retrospective analysis of routinely collected, deidentified data and clinical

procedures followed the standard of care, need for patient informed consent was waived by the IRBs.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. As these data are owned by governments, they are not publicly available. Statistical code available from the corresponding author on request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Caroline E Boeke <http://orcid.org/0000-0003-1939-1307>

REFERENCES

- HCV market intelligence report 2021 and preliminary HBV market insights. Clinton health access initiative 2021, 2021. Available: https://chai19.wpenginepowered.com/wp-content/uploads/2021/08/Hepatitis-C-Market-Report_2021-FINAL-1.pdf
- Boeke CE, Adesigbin C, Agwuocha C, *et al*. Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination. *BMJ Glob Health* 2020;5:e003767.
- Global progress report on HIV. *Viral hepatitis and sexually transmitted infections, 2021*. Geneva: World Health Organization, 2021.
- van Dijk M, Drenth JPH, Arends JE, HepNed study group. Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination. *J Viral Hepat* 2020;27:1270–83.
- Machado SM, Almeida Cde, Pinho JRR, *et al*. Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up. *Rev Saude Publica* 2017;51:40.
- Aleman S, Söderholm J, Büsch K, *et al*. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus. *Liver Int* 2020;40:1832–40.
- Darvishian M, Wong S, Binka M, *et al*. Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies. *J Viral Hepat* 2020;27:243–60.
- Astell-Burt T, Flowerdew R, Boyle P, *et al*. Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? *Soc Sci Med* 2012;75:240–7.
- Del Rio-Valencia JC, Asensi-Diez R, Tamayo-Bermejo R, *et al*. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C. *Rev Esp Quimioter* 2019;32:296–302.
- Yan Z, Wang Y. Viral and host factors associated with outcomes of hepatitis C virus infection (review). *Mol Med Rep* 2017;15:2909–24.
- Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. *J Hepatol* 2016;64:486–504.
- Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? *Hepatology* 2015;62:4–7.
- Barreiro P, Labarga P, Fernandez-Montero JV, *et al*. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. *J Clin Virol* 2015;71:63–6.
- Soriano V, Labarga P, de Mendoza C, *et al*. New hepatitis C therapies for special patient populations. *Expert Opin Pharmacother* 2016;17:217–29.
- World Health Organization. *Guidelines for the care and treatment of persons diagnosed with chronic HCV infection*. Geneva, Switzerland, 2018.
- Ministry of health, Vietnam. guidelines for diagnosis and treatment of hepatitis C virus. Vietnam, 2021 <https://trungtamytehocmon.medinet.gov.vn/van-ban/quyet-dinh-so-2065qd-byt-ngay-29-thang-4-nam-2021-cua-bo-y-te-ve-viec-ban-hanh-vbct13666-44154.aspx>
- Frijters EM, Hermans LE, Wensing AMJ, *et al*. Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries. *AIDS* 2020;34:1261–88.
- Auld AF, Agolory SG, Shiraiishi RW, *et al*. Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004-2013. *MMWR Morb Mortal Wkly Rep* 2014;63:1097–103.
- Balkhy HH, El-Saed A, Sanai FM, *et al*. Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia. *J Infect Public Health* 2017;10:379–87.
- World Health Organization. *Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection*. Geneva, Switzerland, 2022.
- Cooper CL, Hatashita H, Corsi DJ, *et al*. Direct-Acting antiviral therapy outcomes in Canadian chronic hepatitis C telemedicine patients. *Ann Hepatol* 2017;16:874–80.
- Pérez Hernández JL, Higuera de la Tijera M^a de Fátima, Arce Salinas CA. Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience. *Rev Esp Enferm Dig* 2021;113:624–5.
- Tahan V, Almashhrawi A, Mutrux R, *et al*. Show me ECHO-Hepatitis C: a telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries. *Turk J Gastroenterol* 2015;26:447–9.
- Zhang M, O'Keefe D, Craig J, *et al*. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. *Lancet Gastroenterol Hepatol* 2021;6:371–80.
- Zhang M, O'Keefe D, Iwamoto M, *et al*. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. *J Viral Hepat* 2020;27:886–95.
- Solomon SS, Wagner-Cardoso S, Smeaton L, *et al*. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. *Lancet Gastroenterol Hepatol* 2022;7:307–17.
- Castro R, Perazzo H, de Araujo LAMM, *et al*. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: a systematic review with meta-analysis. *PLoS One* 2020;15:e0229143.
- Oru E, Trickey A, Shirali R, *et al*. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. *Lancet Glob Health* 2021;9:e431–45.
- Jong S, Cuca Y, Thompson LM. Meta-Analysis of mobile phone reminders on HIV patients' retention to care. *J Mob Technol Med* 2017;6:5–18.
- Penn AW, Azman H, Horvath H, *et al*. Supportive interventions to improve retention on art in people with HIV in low- and middle-income countries: a systematic review. *PLoS One* 2018;13:e0208814.
- Draper BL, Pedrana A, Howell J, *et al*. Decentralized, community-based hepatitis C point-of-care testing and direct-acting antiviral treatment for people who inject drugs and the general population in Myanmar: protocol for a feasibility study. *JMIR Res Protoc* 2020;9:e16863.
- Rapoud D, Quillet C, Pham Minh K, *et al*. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRUG use & Infections in VIETnam-hepatitis C). *BMJ Open* 2020;10:e039234.
- Thinh VT, Li L, Matthieu D, *et al*. HCV and HIV co-infection among people who inject drugs in Vietnam. *J Health Soc Sci* 2020;5:573–86.

Supplemental Table 1. Predictors of treatment completion within each country based on multivariate GLM model accounting for clustering by facility.¹

	India (Punjab State only)			Indonesia			Myanmar			Nigeria (Nasarawa State only)			Vietnam		
	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	
N	79,894/87,522			5,785/7,297			2,003/2,033			120/139			1,749/1,866		
Total %	91.3%			79.3%			98.5%			86.3%			93.7%		
Sex															
Female	96.0%	Ref		78.5%	Ref		98.7%	Ref		85.5%	Ref		94.6%	Ref	
Male	89.2%	0.47 (0.42-0.53)	<0.001	79.9%	0.87 (0.74-1.02)	0.09	98.4%	0.66 (0.35-1.26)	0.21	87.3%	1.31 (0.59-2.93)	0.51	93.6%	0.79 (0.48-1.32)	0.37
Transgender	88.2%	0.56 (0.17-1.90)	0.36	-	-		-			-	-		-		
Unknown	-			0.0%	-		-			-	-		-		
Age															
12-19	83.5%	Ref		85.7%	Ref		100.0% ²	-		-	-		100.0% ²	-	-
20-29	86.4%	1.18 (1.02-1.37)	0.02	76.2%	0.77 (0.32-1.89)	0.58	97.5%	Ref		100.0% ²	-		91.7%	Ref	
30-39	91.7%	1.81 (1.56-2.11)	<0.001	84.2%	0.83 (0.29-2.34)	0.72	98.9%	2.43 (0.23-25.62)	0.46	83.3% ²	Ref		93.9%	1.32 (0.88-1.96)	0.17
40-49	94.8%	2.77 (2.30-3.33)	<0.001	80.8%	1.04 (0.38-2.87)	0.94	98.6%	2.51 (0.30-20.72)	0.39	83.3%	1.12 (0.15-8.57)	0.91	93.9%	1.46 (1.00-2.13)	0.05
50-59	94.5%	2.77 (2.41-3.18)	<0.001	76.4%	0.89 (0.35-2.29)	0.81	99.1%	4.79 (0.74-30.95)	0.10	90.2%	2.27 (0.62-8.30)	0.22	94.3%	1.60 (1.11-2.29)	0.01
60-69	93.1%	2.23 (1.86-2.67)	<0.001	74.6%	0.85 (0.33-2.16)	0.73	97.1%	1.78 (0.33-9.66)	0.50	80.0%	0.87 (0.20-3.86)	0.86	92.4%	1.06 (0.70-1.59)	0.79
70+	90.0%	1.57 (1.31-1.88)	<0.001	72.4%	0.70 (0.25-1.97)	0.50	99.3%	8.06 (1.35-48.10)	0.02	83.3%	1.08 (0.09-12.48)	0.95	93.2%	1.26 (0.72-2.20)	0.41
Missing	91.1%	2.00 (1.00-3.98)	0.05	76.9%	0.58 (0.17-1.99)	0.39	100.0% ²	-	-	-			-		
Family history of HCV															
Yes	84.1%	0.69 (0.55-0.86)	0.001	-	-	-	99.5%	2.57 (0.71-9.37)	0.15	100.0% ²			-	-	-

None Reported	91.3%	Ref		-	-	-	98.4%	Ref		86.2%		-	-	-
History of injecting drugs														
Yes	76.8%	0.75 (0.57-0.98)	0.03	88.4%	1.79 (1.32-2.41)	<0.001	99.6%	4.70 (0.73-30.19)	0.10	-		93.8%	0.92 (0.61-1.37)	0.67
None reported	92.0%	Ref		76.8%	Ref		98.4%	Ref		86.3%		93.7%	Ref	
Known HIV co-infection														
Yes	75.3%	-	-	84.7%	-	-	98.8%	-	-	100.0% ₂		94.8%	-	-
No	91.6%	-	-	77.7%	-	-	98.4%	-	-	86.0%		93.2%	-	-
Known HBV co-infection														
Yes	33.3% ₂	-	-	-	-	-	100.0%	-	-	100.0%		93.1%	-	-
No	91.3%	-	-	-	-	-	98.5%	-	-	85.3%		93.8%	-	-
Cirrhosis														
Compensated	89.8%	1.03 (0.87-1.22)	0.73	-	-	-	98.3%	2.98 (1.14-7.84)	0.03	-		92.1%	0.61 (0.43-0.87)	0.01
Decompensated	79.5%	0.46 (0.34-0.62)	<0.001	-	-	-	99.4%	9.85 (0.51-188.88)	0.13	-		93.2%	0.62 (0.49-0.78)	<0.001
Cirrhotic (no additional information)	88.4%	1.06 (0.81-1.39)	0.66	69.6%	0.92 (0.43-1.98)	0.83	-	-	-	100.0% ₂		-	-	-
Non-cirrhotic	91.7%	Ref		85.2%	Ref		98.5%	Ref		85.6%		94.8%	Ref	
Unknown	-	-	-	50% ²	0.20 (0.06-0.68)	0.01		-	-				-	-
Treatment regimen														
SOF/DCV	91.6%	Ref		78.9%	Ref		98.5%	-	-	86.3%		94.1%	Ref	
SOF/DCV+RBV	64.2%	0.17 (0.05-0.66)	0.01	90.4%	1.41 (0.76-2.63)	0.28	-	-	-	-		93.1%	1.05 (0.80-1.37)	0.74
SOF/VEL	89.8%	0.99 (0.79-1.24)	0.94	-	-	-	-	-	-	-		-	-	-
SOF/VEL+RBV	90.3%	0.91 (0.71-1.17)	0.47	-	-	-	-	-	-	-		-	-	-
Other	85.2%	0.34 (0.13-0.88)	0.03	80.0%	0.92 (0.55-1.56)	0.76	-	-	-	-		-	-	-
Treatment duration														
12 weeks	91.8%	Ref		85.5%	Ref		99.3%	Ref		85.6%		93.9%	Ref	

24 weeks	86.5%	0.34 (0.27-0.44)	<0.001	68.9%	0.38 (0.18-0.83)	0.02	96.9%	0.10 (0.02-0.40)	0.001	100.0% ²			91.8%	0.93 (0.75-1.17)	0.55
Other	97.2%	2.29 (0.84-6.25)	0.11	-	-	-	-	-	-	-			100.0% ²	-	-
Year of treatment initiation		0.65 (0.60-0.71)	<0.001		0.69 (0.60-0.80)	<0.001		0.41 (0.18-0.94)	0.04		0.47 (0.37-0.59)	<0.001		0.53 (0.35-0.80)	0.003
2016	97.1%			-			-			0.0% ²			-		
2017	94.0%			82.8%			98.7%			100.0%			95.8%		
2018	92.3%			86.0%			97.7%			91.7%			92.4%		
2019	86.9%			84.6%			-			79.4%			100.0% ²		
2020	83.6%			76.9%			-			-			-		
2021	80.1%			66.2%			-			-			-		
2022	-			0.0%			-			-			-		

¹Patients who died were excluded from this analysis, as the data did not consistently indicate the timing of death (pre- or post-treatment completion).

²Sample size was <10 people in this category.

Supplemental Table 2. Predictors of cure (confirmed by SVR12) within each country based on multivariate GLM model accounting for clustering by facility.¹

	India (Punjab State only)			Indonesia			Myanmar			Nigeria (Nasarawa State only) ⁴			Vietnam		
	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P
N	58,902/63,746			2,576/2,667			1,648/1,826			36/39			1,143/1,151		
Total %	92.4%			96.6%			90.3%			92.3%			99.3%		
Sex															
Female	95.0%	Ref		96.5%	Ref		92.2%	Ref		92.9%	-	-	98.5%	Ref	
Male	91.0%	0.61 (0.44-0.85)	0.004	96.6%	1.07 (0.68-1.70)	0.77	88.4%	0.62 (0.46-0.84)	0.002	90.9%	-	-	99.5%	3.63 (1.23-10.72)	0.02
Transgender	100.0%	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Age															
12-19	84.5% ²	Ref		100.0%	-	-	50.0% ³	Ref		-	-	-	100.0% ³	-	-
20-29	87.5%	1.26 (1.04-1.52)	0.02	94.6%	Ref		93.9%	16.89 (3.09-92.49)	0.001	100.0% ³	-	-	100.0%	-	-
30-39	93.4%	2.39 (1.91-3.00)	<0.001	97.7%	2.35 (1.17-4.71)	0.02	93.0%	14.36 (1.27-162.83)	0.03	90.0%	-	-	99.0%	Ref	
40-49	94.4%	2.77 (1.96-3.92)	<0.001	95.2%	1.10 (0.48-2.53)	0.82	89.0%	8.82 (0.69-112.21)	0.09	100.0% ³	-	-	99.5%	2.09 (1.04-4.17)	0.04

50-59	94.4%	2.75 (1.95-3.8)	<0.001	95.9%	1.25 (0.55-2.88)	0.59	89.5%	9.29 (0.63-137.01)	0.10	100.0%	-	-	100.0%	-	-
60-69	93.7%	2.44 (1.70-3.49)	<0.001	97.6%	2.12 (0.95-4.75)	0.07	91.2%	11.04 (0.88-138.51)	0.06	66.7% ³	-	-	100.0%	-	-
70+	94.3%	2.78 (2.02-3.82)	<0.001	98.1%	2.74 (0.93-8.13)	0.07	90.2%	9.90 (0.83-118.60)	0.07	100.0% ³	-	-	96.0%	0.47 (0.24-0.93)	0.03
Missing	93.6%	2.49 (1.21-5.12)	0.01	95.5%	1.16 (0.20-6.71)	0.87	-	-	-	-	-	-	-	-	-
Family history of HCV															
Yes	97.9%	3.83 (2.59-5.67)	<0.001	-	-	-	91.4%	1.05 (0.58-1.91)	0.88	100.0% ³	-	-	-	-	-
None Reported	92.4%	Ref		-	-	-	90.1%	Ref		92.1%	-	-	-	-	-
History of injecting drugs															
Yes	84.6%			96.0%			86.1%			92.3%			99.6%		
None reported	92.6%			96.8%			90.8%			-			99.1%		
Known HIV co-infection															
Yes	83.2%			97.0%			89.7%			100.0% ³			99.6%		
No	92.5%			96.4%			90.6%			92.1%			99.1%		
Known HBV co-infection															
Yes	-	-	-	-	-	-	92.1%	1.38 (0.40-4.76)	0.61	66.7% ³	-	-	98.2%	0.22 (0.05-0.93)	0.04
No	92.4%	-	-	-	-	-	90.2%	Ref		94.4%	-	-	99.4%	Ref	
Cirrhosis															
Compensated	93.0%	0.74 (0.50-1.08)	0.12	-	-	-	90.0%	0.88 (0.65-1.20)	0.42	-	-	-	99.2%	1.81 (0.57-5.78)	0.32
Decompensated	93.7%	0.82 (0.55-1.23)	0.34	-	-	-	86.4%	0.62 (0.46-0.84)	0.002	-	-	-	100.0%	-	-
Cirrhotic (no additional information)	91.5%	0.74 (0.54-1.00)	0.05	97.0%	1.22 (0.68-2.17)	0.51	-	-	-	100.0% ³	-	-	-	-	-
Non-cirrhotic	92.4%	Ref		96.4%	Ref		90.7%	-	-	91.7%	-	-	99.3%	Ref	
Unknown	-	-	-	100.0% ³			-	-	-	-	-	-	-	-	-
Treatment regimen															
SOF/DCV	92.1%	Ref		96.5%	Ref		90.3%	-	-	92.3%	-	-	99.5%	Ref	

SOF/DCV+RBV	81.0%	0.37 (0.10- 1.36)	0.14	97.7%	1.37 (0.37- 5.00)	0.64	-	-	-	-	-	-	99.0%	0.31 (0.02- 3.96)	0.37
SOF/VEL	91.7%	0.96 (0.69- 1.34)	0.82	-	-	-	-	-	-	-	-	-	-	-	-
SOF/VEL+RBV	94.4%	1.45 (1.27- 1.65)	<0.001	-	-	-	-	-	-	-	-	-	-	-	-
Other	86.4%	-	-	96.7%	1.13 (0.57- 2.24)	0.72	-	-	-	-	-	-	-	-	-
Treatment duration															
12 weeks	92.2%	-	-	96.4%	-	-	90.1%	-	-	91.7%	-	-	99.3%	-	-
24 weeks	93.9%	-	-	97.0%	-	-	90.5%	-	-	100.0% ³	-	-	100.0%	-	-
Other	94.2%	-	-	-	-	-	-	-	-	-	-	-	100.0% ³	-	-
Year of treatment initiation															
2016	94.2%	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2017	91.4%	-	-	97.8%	-	-	90.1%	-	-	100.0% ³	-	-	99.1%	-	-
2018	93.4%	-	-	95.6%	-	-	91.2%	-	-	87.5%	-	-	99.5%	-	-
2019	90.8%	-	-	96.7%	-	-	-	-	-	100.0% ³	-	-	100.0% ³	-	-
2020	90.8%	-	-	96.7%	-	-	-	-	-	-	-	-	-	-	-
2021	76.9%	-	-	96.1%	-	-	-	-	-	-	-	-	-	-	-

¹Among those who completed SVR12 testing.

²This group demonstrated statistically significant differences from other groups (combined) in a chi-square analyses accounting for clustering by health facility.

³Sample size was <10 people in this category.

⁴Country not modeled due to small sample sizes.